<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01982396</url>
  </required_header>
  <id_info>
    <org_study_id>PENTA 13</org_study_id>
    <nct_id>NCT01982396</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children</brief_title>
  <acronym>PENTA 13</acronym>
  <official_title>Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PENTA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-over 28 week study of the plasma pharmacokinetic profiles of twice daily 3TC
      (4mg/kg/dose BD) with once daily 3TC (8mg/kg/dose OD) and twice daily ABC (8mg/kg/dose BD)
      with daily ABC (16mg/kg/dose OD) where one or both drugs are being taken as part of
      combination antiretroviral therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">February 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC) of lamivudine after qd and bid dosing</measure>
    <time_frame>week 0 and Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of lamivudine after qd and bid dosing</measure>
    <time_frame>week 0 and week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of lamivudine after qd and bid dosing</measure>
    <time_frame>week 0 and week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of abacavir after qd and bid dosing</measure>
    <time_frame>week 0 and week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin of abacavir after qd and bid dosing</measure>
    <time_frame>week 0 and week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of abacavir after qd and bid dosing</measure>
    <time_frame>week 0 and week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe trough intracellular levels of 3TC on twice daily and once daily dosage regimens</measure>
    <time_frame>Week 0 and week 4</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To describe patient and family acceptability of and adherence to once daily compared to twice daily dosing</measure>
    <time_frame>week -2 and week 24</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Twice daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC Twice Daily</intervention_name>
    <arm_group_label>Twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABC Once Daily</intervention_name>
    <arm_group_label>Once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC Once Daily</intervention_name>
    <arm_group_label>Once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3TC Twice Daily</intervention_name>
    <arm_group_label>Twice daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with definitive HIV infection

          -  Age &gt; 2 and &lt; 13 years

          -  Currently on combination ART including 3TC and / or ABC, for at least 6 months, with
             stable CD4 cell count and HIV RNA viral load and expected to stay on this regimen for
             at least a further 3 months.

        Exclusion Criteria:

          -  â€¢ Intercurrent illness

               -  Receiving concomitant therapy except prophylaxis against Pneumocystis carinii
                  pneumonia (PCP)

               -  Abnormal renal or liver function (grade 3 or above)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vas Novelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Ormond Street Hospital for Children, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hermione Lyall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Mary's Hospital, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.penta-id.org/hiv/penta-trials/penta-trials-publications/49-penta-13.html</url>
    <description>PENTA 13 publications and presentations</description>
  </link>
  <reference>
    <citation>Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, Walker S, Novelli V, Lyall H, Khoo S, Gibb D; PENTA-13 Study Group. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther. 2005;10(2):239-46.</citation>
    <PMID>15865218</PMID>
  </reference>
  <reference>
    <citation>LePrevost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM; Pediatric European Network for the Treatment of AIDS 13 Study Group. Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J. 2006 Jun;25(6):533-7.</citation>
    <PMID>16732152</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>paediatric</keyword>
  <keyword>Abacavir</keyword>
  <keyword>lamivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

